Orum Therapeutics
![BMS Acquires Orum's ADC ORM-6151 for AML and MDS Treatment](https://pharmtales.com/wp-content/uploads/2023/11/BMS-Acquires-Orums-ADC-ORM-6151-for-AML-Treatment.jpg)
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Anika Sharma
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...